US biotechnology company Klotho Neurosciences Inc (NASDAQ:KLTO) said on Thursday that it is evaluating the acquisition of several complementary technologies aimed at supporting healthy brain function, organ health, and longevity.

In addition to its core programs targeting brain aging and neurodegenerative diseases such as ALS, Alzheimer's, and Parkinson's, the company is now seeking to expand into adjacent technologies that complement its proprietary anti-aging Klotho platform. The company's goal is to slow biological aging and reduce the burden of age-related diseases -- ultimately promoting a longer, healthier life.

"As announced previously, we've begun manufacturing and clinical development of KLTO-101 and KLTO-202," said Klotho CEO Dr. Joseph Sinkule. "We're also exploring other treatments that could support healthy aging and extend human longevity."

According to the company, the human Klotho gene is strongly linked to aging and longevity. Klotho levels decline with age, contributing to age-related disorders such as cardiometabolic disease, neurodegeneration, cancer, sarcopenia (muscle wasting), osteoporosis, and general fatigue. Silencing of the Klotho gene has been shown to accelerate multi-organ deterioration.